Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley spoke with Proactive Investors at the MicroCap Conference in New York.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist.
Price: 1.24 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
Retail & consumer
Helix Technologies (OTCQB: HLIX) President of Data Services Garvis Toler joined Steve Darling from Proactive Vancouver to discuss the company releasing their 2019 financial numbers which were very strong and also what milestones they hit to close the year. Toler also told Proactive...
Retail & consumer
Full interview: Naturally Splendid hits major milestone with...
Industry & services
Full interview: Atlas Engineered Products feels well positioned to...
Prev article
